Inside Trade: David Neithercut Unloaded 25,000 Shares of Equity Residential (EQR); Contravir Pharmaceuticals (CTRV) Shorts Raised By 0.47%

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) Logo

Contravir Pharmaceuticals Inc (NASDAQ:CTRV) had an increase of 0.47% in short interest. CTRV’s SI was 4.03M shares in June as released by FINRA. Its up 0.47% from 4.01 million shares previously. With 642,900 avg volume, 6 days are for Contravir Pharmaceuticals Inc (NASDAQ:CTRV)’s short sellers to cover CTRV’s short positions. The SI to Contravir Pharmaceuticals Inc’s float is 5.52%. The stock decreased 8.81% or $0.14 during the last trading session, reaching $1.45. About 116,505 shares traded. ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) has declined 62.08% since June 14, 2017 and is downtrending. It has underperformed by 74.65% the S&P500. Some Historical CTRV News: ; 30/05/2018 – ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical; 30/05/2018 – CONTRAVIR PHARMACEUTICALS – CRV431, REDUCES DEVELOPMENT, PROGRESSION OF LIVER TUMORS IN PRECLINICAL HEPATOCELLULAR CARCINOMA STUDY; 30/05/2018 – ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study; 31/05/2018 – ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model; 30/05/2018 – CONTRAVIR PHARMACEUTICALS INC – NEW DATA PROVIDES EVIDENCE THAT CRV431 CAN ALSO REDUCE AMOUNT AND SIZE OF TUMORS IN HEPATOCELLULAR CARCINOMA; 19/04/2018 DJ ContraVir Pharmaceuticals Inc, Inst Holders, 1Q 2018 (CTRV); 30/05/2018 – CONTRAVIR PHARMACEUTICALS – 25% OF CRV431-TREATED MICE HAD NO LIVER TUMORS AT 10 WEEK STUDY END, ALL VEHICLE-TREATED MICE HAD AT LEAST 5 TUMORS/LIVER; 24/05/2018 – ContraVir Pharmaceuticals: Reverse Stk Split to Bring Co Into Compliance With Nasdaq Cap Market; 31/05/2018 – ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Liver Fibrosis in a Preclinical Model; 31/05/2018 – ContraVir Pharma: CRV431 Decreased Extent of Fibrosis in Animal Model by 46% Compared to Vehicle Control

More notable recent ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) news were published by: which released: “An Open Letter To ContraVir Pharmaceuticals’ Management” on June 06, 2018, also with their article: “ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record” published on June 12, 2018, published: “ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split” on May 24, 2018. More interesting news about ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) were released by: and their article: “ContraVir Pharmaceuticals to Present at 2018 BIO International Convention” published on May 29, 2018 as well as‘s news article titled: “ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering” with publication date: June 05, 2018.

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical firm focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus infections. The company has market cap of $15.50 million. The firm is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. It currently has negative earnings.

Since February 7, 2018, it had 0 insider buys, and 13 selling transactions for $5.12 million activity. The insider Manelis Michael L sold 1,000 shares worth $57,618. The insider Parrell Mark J. sold 7,355 shares worth $427,929. On Wednesday, February 7 the insider Brackenridge Alexander sold $47,651. Fenster Scott sold $26,124 worth of stock. On Wednesday, May 23 the insider Santee David S sold $118,676. Sorenson Christa L also sold $6,807 worth of Equity Residential (NYSE:EQR) shares. The insider Altshuler Barry sold 5,182 shares worth $316,864.

Analysts await Equity Residential (NYSE:EQR) to report earnings on July, 24. They expect $0.80 EPS, up 3.90% or $0.03 from last year’s $0.77 per share. EQR’s profit will be $305.80M for 19.75 P/E if the $0.80 EPS becomes a reality. After $0.77 actual EPS reported by Equity Residential for the previous quarter, Wall Street now forecasts 3.90% EPS growth.

Equity Residential is an S&P 500 firm focused on the acquisition, development and management of rental apartment properties in urban and high-density suburban coastal gateway markets where today's renters want to live, work and play. The company has market cap of $24.16 billion. Equity Residential owns or has investments in 305 properties consisting of 78,302 apartment units, primarily located in Boston, New York, Washington, D.C., Seattle, San Francisco and Southern California. It has a 38.82 P/E ratio.

Among 25 analysts covering Equity Residential (NYSE:EQR), 7 have Buy rating, 1 Sell and 17 Hold. Therefore 28% are positive. Equity Residential has $91 highest and $60.0 lowest target. $71.16’s average target is 12.59% above currents $63.2 stock price. Equity Residential had 88 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Hold” on Monday, November 27. As per Friday, May 26, the company rating was maintained by BMO Capital Markets. On Thursday, August 25 the stock rating was initiated by BTIG Research with “Neutral”. As per Monday, July 18, the company rating was maintained by Deutsche Bank. RBC Capital Markets maintained the stock with “Hold” rating in Friday, October 20 report. The stock of Equity Residential (NYSE:EQR) has “Hold” rating given on Tuesday, July 25 by BMO Capital Markets. On Wednesday, March 30 the stock rating was downgraded by Citigroup to “Neutral”. RBC Capital Markets maintained the stock with “Hold” rating in Friday, July 14 report. The firm has “Sell” rating by Miller Tabak given on Monday, November 9. The stock of Equity Residential (NYSE:EQR) has “Buy” rating given on Friday, February 9 by Mizuho.

The President & CEO of Equity Residential and firm’s insider David Neithercut unloaded 25,000 shares of the corporation based on the market price per share of $64.5 of a share. These insider shares had a value of roughly $1,612,500 USD. Now, David Neithercut has a total of 111,262 shares or 0.03% of the company’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding).

Investors sentiment decreased to 0.86 in Q1 2018. Its down 0.25, from 1.11 in 2017Q4. It fall, as 57 investors sold Equity Residential shares while 155 reduced holdings. 46 funds opened positions while 136 raised stakes. 335.09 million shares or 1.15% less from 338.98 million shares in 2017Q4 were reported. Paloma Prns Management Communication reported 6,579 shares. Credit Agricole S A owns 2,642 shares. Putnam Invests Ltd Liability Corporation accumulated 361,765 shares. Davis Selected Advisers has 221,390 shares. Focused Wealth holds 298 shares. Oppenheimer & Inc owns 27,036 shares or 0.04% of their US portfolio. Great West Life Assurance Com Can accumulated 545,747 shares or 0.08% of the stock. Pub Sector Pension Inv Board holds 0.01% or 20,579 shares in its portfolio. Eii Cap Mngmt holds 78,538 shares. 81,949 are owned by Honeywell. 147,167 were accumulated by Bancorporation Of Nova Scotia. Fiduciary Tru Co stated it has 59,091 shares or 0.11% of all its holdings. The Michigan-based State Treasurer State Of Michigan has invested 0.05% in Equity Residential (NYSE:EQR). Balasa Dinverno And Foltz Limited Com has invested 0.09% in Equity Residential (NYSE:EQR). Moreover, Waterfront Prns Ltd Liability Company has 1.18% invested in Equity Residential (NYSE:EQR) for 159,447 shares.

Equity Residential (NYSE:EQR) Institutional Positions Chart